|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500110921 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-22 16:56:42 |
|
注册时间: Date of Registration: |
2025-10-22 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
早期CPAP治疗对卒中合并OSA患者认知与功能的改善及血清NfL、GFAP在其中的预测价值 |
|
Public title: |
Early CPAP Intervention Improves Cognition and Function in Stroke Patients with OSA: Predictive Roles of Serum NfL and GFAP as Biomarkers |
|
注册题目简写: |
早期使用呼吸机治疗对中风后打鼾严重患者认知功能和日常活动能力的改善效果研究——兼探血液指标在其效果预测中的作用 |
|
English Acronym: |
Improving Memory and Daily Living after a Stroke: How Breathing Support during Sleep Can Help & The Role of a Simple Blood Test |
|
研究课题的正式科学名称: |
早期CPAP治疗对卒中合并OSA患者认知与功能的改善及血清NfL、GFAP在其中的预测价值 |
|
Scientific title: |
Early CPAP Intervention Improves Cognition and Function in Stroke Patients with OSA: Predictive Roles of Serum NfL and GFAP as Biomarkers |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赵荣健 |
研究负责人: |
赵荣健 |
|
Applicant: |
Zhao Rongjian |
Study leader: |
Zhao Rongjian |
|
申请注册联系人电话: Applicant telephone: |
+86 181 9285 1035 |
研究负责人电话:
Study leader's |
+86 29 8365 7930 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
z42423823@163.com |
研究负责人电子邮件: Study leader's E-mail: |
z42423823@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市新城区咸宁东路512号西北大学第一医院 |
研究负责人通讯地址: |
新城区咸宁东路512号 |
|
Applicant address: |
Northwestern University First Hospital, No. 512 Xianning East Road, Xincheng District, Xi'an Cit |
Study leader's address: |
No. 512 Xianning East Road, Xi'an City, Shaanxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
西北大学第一医院 |
||
|
Applicant's institution: |
Northwestern University First Hospital |
||
|
研究负责人所在单位: |
西北大学第一医院 |
||
|
Affiliation of the Leader: |
Northwestern University First Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XDYY伦审2025-04 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
西北大学第一医院伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of Northwest University First Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-06 00:00:00 | ||
|
伦理委员会联系人: |
杨华 |
||
|
Contact Name of the ethic committee: |
Yang Hua |
||
|
伦理委员会联系地址: |
新城区咸宁东路512号 |
||
|
Contact Address of the ethic committee: |
No. 512 Xianning East Road, Xi'an City, Shaanxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 29 8953 1040 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
284159397@qq.com |
|
研究实施负责(组长)单位: |
西北大学第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Northwestern University First Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
新城区咸宁东路512号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 512 Xianning East Road, Xi'an City, Shaanxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
2025年院级科研基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
2025 College-level scientific research fund project |
||||||||||||||||||||||
|
研究疾病: |
本研究聚焦于急性缺血性或出血性卒中与阻塞性睡眠呼吸暂停(OSA) 的共病群体。研究核心关注由此共病状态引发或加重的两大核心症候群:卒中后认知障碍(PSCI),具体表现为注意力不集中、记忆力下降、执行功能受损及信息处理速度减慢;以及卒中后神经功能残疾,包括运动功能障碍(如偏瘫、平衡困难)、感觉障碍及日常活动能力下降。同时,本研究也涵盖OSA相关的典型症状,如夜间打鼾、呼吸暂停、日间过度嗜睡及疲劳。为 |
||||||||||||||||||||||
|
Target disease: |
This study focused on the comorbidity population of acute ischemic or hemorrhagic stroke and obstructive sleep apnea (OSA). The core of the study focuses on two core syndromes that are caused or exacerbated by this comorbid state: post-stroke cognitive impairment (PSCI), which manifests as difficulty concentrating, memory loss, impaired executive function, and slowed information processing; and po |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
II期临床试验 | ||||||||||||||||||||||
|
Study phase: |
2 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
验证早期CPAP治疗对卒中合并中重度OSA患者认知与功能的改善作用;明确血清NfL和GFAP水平变化在治疗效果及病情进展中的预测价值;确定CPAP治疗的最佳干预时间窗口,助力制定科学干预方案,为卒中合并OSA患者提供精准治疗的生物学标志物,为个体化管理提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To verify the effect of early CPAP therapy on the improvement of cognition and function in patients with moderate to severe OSA after stroke. To clarify the predictive value of serum NfL and GFAP levels in treatment effect and disease progression. Determine the optimal intervention time window for CPAP therapy, help formulate scientific intervention plans, provide biological markers for precise treatment for patients with stroke and OSA, and provide a scientific basis for individualized management. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经CT或MRI诊断为急性脑梗死;(2)符合国际睡眠疾病分类 第3版(international classification of sleep disorders-third edition,ICSD-3)诊断标准符合成人OSA诊断标准:需要具备以下1)+(2)/(3)。1)以下表现至少出现1项:①主诉困倦、 非恢复性睡眠、乏力或失眠;②因憋气或喘息 从睡眠中醒来;③同寝室或其他目击者报告患 者在睡眠期间存在习惯性打鼾、呼吸中断或两 者皆有;④已确诊高血压、心境障碍、认知障碍、 冠心病、脑血管疾病、充血性心力衰竭、心房颤 动或2型糖尿病。2)PSG或者睡眠中心外睡眠监测(out of center sleep test,OCST)证实监测期间发生呼吸事件≥5次/小时,包括阻塞性呼吸暂 停、混合性呼吸暂停、低通气和呼吸努力相关性觉醒。3)PSG或OCST证实监测期间发生呼吸事件≥15次/小时,包括阻塞性呼吸暂停、混合性呼吸暂停、低通气和RERAs;并且AHI≥20/h的患者。(3)年龄18-80岁;(4)卒中发病后2周内;(5)意识清楚,能完成简单指令;(6)提供知情同意的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Acute cerebral infarction diagnosed by CT or MRI; 2. Meet the diagnostic criteria of the International Classification of Sleep Disorders-third edition (ICSD-3) and meet the diagnostic criteria for OSA in adults: the following 1) 2) 3) are required. (1) At least one of the following manifestations: 1) complaints of drowsiness, non-restorative sleep, fatigue or insomnia; 2) waking up from sleep due to holding breath or wheezing; 3) Residents in the same dormitory or other witnesses report habitual snoring, interruption of breathing, or both during sleep; 4) Confirmed hypertension, mood disorders, cognitive impairment, coronary heart disease, cerebrovascular disease, congestive heart failure, atrial fibrillation, or type 2 diabetes. (2) PSG or out-of-center sleep test (OCST) confirmed that respiratory events occurred during >= 5 times/hour during the monitoring period, including obstructive apnea, mixed apnea, hypopnea, and respiratory effort-related awakenings. (3) PSG or OCST confirmed that respiratory events occurred during >= 15 times/hour during monitoring, including obstructive apnea, mixed apnea, hypopnea, and RERAs, and patients with an AHI >= 20/h. 3. Age 18-80 years old; 4. within 2 weeks after the onset of stroke; 5. Clear consciousness and able to complete simple instructions; 6. Patients who provide informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.创伤性脑损伤或脑肿瘤史;(2)诊断为轻度阻塞性睡眠呼吸暂停(OSA)或中枢性睡眠呼吸暂停或混合性睡眠呼吸暂停;(3)基线氧饱和度<95%;(4)存在影响肺功能的急性或慢性心肺疾病;(5)存在神经肌肉疾病(如肌萎缩性侧索硬化症和肌无力);(6)其他重要器官功能严重障碍、病情不稳定的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. History of traumatic brain injury or brain tumor; 2. Diagnosis of mild obstructive sleep apnea (OSA) or central sleep apnea or mixed sleep apnea; 3. Baseline oxygen saturation < 95%; 4. Acute or chronic cardiopulmonary disease affecting lung function; 5. Presence of neuromuscular diseases (such as amyotrophic lateral sclerosis and muscle weakness); 6. Patients with severe dysfunction of other important organs and unstable condition. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2027-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-10-30 00:00:00 至 To 2027-03-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由独立的方法学人员,使用权威的随机数字表,通过规定起始点、读取方向和奇偶分配规则,并结合区组随机化策略,来产生随机序列。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random sequences are generated by independent methodologists using authoritative random number tables by specifying the starting point, reading direction, and parity allocation rules, combined with block randomization strategies. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲,对评估者隐藏分组 |
|
Blinding: |
Single blind study with blinded-evaluators |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究产生的数据因涉及患者隐私及项目支持单位等原因目前暂无法公开提供网络地址。但可向通讯作者申请,在满足数据访问协议条款的前提下获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The data generated in this study cannot be publicly provided due to patient privacy and project support units. However, it may be obtained upon request from the corresponding author, subject to the terms of the data access agreement. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集将遵循预定的标准操作程序,并通过电子病例报告表实现 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection will follow predetermined standard operating procedures and will be implemented via electronic case report forms |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |